{"Title": "Prostate cancer: Cabazitaxel - A key therapeutic option in prostate cancer", "Year": 2015, "Source": "Nat. Rev. Urol.", "Volume": "12", "Issue": 6, "Art.No": null, "PageStart": null, "PageEnd": null, "CitedBy": 5, "DOI": "10.1038/nrurol.2015.98", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84930754959&origin=inward", "Abstract": "\u00a9 2015 Macmillan Publishers Limited. All rights reserved.Treatment with cabazitaxel is associated with improved survival in patients with metastatic castration-resistant prostate cancer. Bahl et al. recently reported that patient-reported quality-of-life metrics were stable-with a trend towards improvements with increasing numbers of treatment cycles-in 112 patients treated with cabazitaxel in the UK.", "AuthorKeywords": null, "IndexKeywords": ["Antineoplastic Agents", "Biomarkers, Tumor", "Bone Neoplasms", "Caenorhabditis elegans Proteins", "Health Status Indicators", "Humans", "Male", "Prostatic Neoplasms, Castration-Resistant", "Quality of Life", "Taxoids", "Ubiquitin-Conjugating Enzymes"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 0, "EID": "2-s2.0-84930754959", "SubjectAreas": [["Urology", "MEDI", "2748"]], "AuthorData": {"56667360900": {"Name": "Jayaram A.", "AuthorID": "56667360900", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}, "9740870900": {"Name": "Attard G.", "AuthorID": "9740870900", "AffiliationID": "60010337", "AffiliationName": "Institute of Cancer Research"}}}